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The above discussion has allowed us to propose the following hypothesis to address the mechanism of down-regulation of TGF-beta receptors in prostate cancer cells. We hypothesize that prostate cancer cells, in response to TGF-beta stimulation, will down-regulate the expression of TGF-beta receptors through ERK activation, which in term induces the expression of DNA methyltransferases leading to promoter hypermethylation of the TGF-beta receptor genes and down-regulation of expression of TGF-beta receptors. Since epigenetic events can be reversed, we will determine if the use of TGF-beta antibody can reverse this downregulation of TGF-beta receptors in prostate cancer cells. Many advanced tumors are immunosuppressive due, at least in part, to their ability to secrete large amounts of TGF-beta (Letterio and Roberts, 1998; Wojtowicz- Praga, 1997 Praga, , 2003 Pinkas and Teicher, 2006) . Since TGF-beta is a potent immunosuppressant, a gradient of TGF-beta surrounding the tumor site renders the host immune surveillance system ineffective against tumor cells (de Visser and Kast, 1999) . However, despite intense investigation on this topic, the mechanism of TGFbeta in immune suppression remains unclear. The recent recognition that CD4+CD25+ T regulatory cells can suppress anti-tumor immunity has offered a mechanism for tumor evasion of host immune surveillance (Sakaguchi et al, 1995; Shimizu et al, 1999; Sasada et al, 2003) . We have demonstrated the generation of CD4+CD25+ T regulatory cells in the tumor parenchyma through tumor-derived TGF-beta (Liu et al, 2007) . Others have confirmed our results in different tumor systems (Jarnicki et al, 2007; Selvaraj and Geiger, 2007) . This discovery is exciting as it explains at least in part the role of TGF-beta in evasion of host immune surveillance program by the tumor cells. Most recently, we have further discovered that Foxp3 expression (a marker for T regulatory cells) is mediated through TGF-beta induced ERK inactivation . These discoveries describe a new paradigm in TGF-beta action in evasion of the host immune surveillance by tumor cells; and, in the present proposal, we propose to test if ERK inactivation actually mediates promoter demethylation in the Foxp3 gene.
Our recent discoveries indicated that tumor derived TGF-beta was responsible for the generation of CD4+CD25+ T regulatory cells from CD4+CD25-T cells (Liu et al, 2007) and that TGF-beta inactivates ERK in T cells which led to the expression of Foxp3, a marker for T regulatory cells . These findings are exciting and allow us to postulate the hypothesis that tumor-derived TGF-beta leads to ERK inactivation and to promoter de-methylation in the Foxp3 gene of T cells. The use of TGF-beta antibody will reverse this process. This hypothesis is proposed with the understanding that activated ERK is a potent inducer of DNA methyltransferases (Oelke and Richardson, 2004; Lu Q et al, 2005; Lu R et al, 2007) . Using neutralizing TGFbeta antibody for treating cancer is a plausible approach, as it alters the tumor micro-environment. In light of the current on-going Phase I clinical trial, the safety and efficacy of using TGF-beta antibody must be carefully evaluated in a pre-clinical setting. The use of TGF-beta antibody may actually pose a risk of promoting certain cancers, when the particular cancer is sensitive to TGF-beta and low doses are administered. Using TGF-beta antibody can also allow us to elucidate mechanisms of TGF-beta action. The status of TGF-beta mediated ERK activation in tumor cells as well as in T cells plays a critical role in tumor progression and metastasis. A successful conclusion of this research will not only allow us to gain new insights into the role of TGF-beta mediated ERK activation in prostate cancer progression but also will pave the way for a clinical trial in prostate cancer patients using the humanized TGF-beta antibody (GC1008; Genzyme Corporation).
At the time of this report, we have completed studies described in Aim 1, Aim 3 and part of Aim 2. Currently, studies described in Aim 2 are underway. Briefly, the progress can be summarized by two papers published recently ). In the first paper , we reported an interesting phenomenon of differential response to TGF-beta between benign and malignant prostate epithelial cells. In the second paper we reported that this differential response to TGF-beta in malignant cells will lead to an up-regulation of DNMT, which will result in a down-regulation of TGF-beta type II receptor in malignant cells. In indicated experiments, cells were transduced with TGF-β receptor II-dominant negative (TβRIIDN) retroviral vector or the GFP vector as previously described. Figure 1A is a schematic diagram of the murine stem cell virus (MSCV) retroviral construct containing a truncated sequence of the human TβRIIDN, lacking the intracellular kinase signaling domain, which was cloned into the pMig-internal ribosomal entry sequence (IRES)-GFP vector. The control construct (not shown) contained the GFP vector only and without the TβRIIDN sequences (325-902 bp). The transduction efficiency was >90%. As indicated in Figure 1B , the basal level of TGF-β1 in DU145 and PC3 was significantly higher than that in BPH1 and RWPE1. These results verified the well-documented phenomenon that prostate cancer cells secrete more TGF-β1 than that of benign cells. 1 When cells were rendered insensitive to TGF-β1 by transduction with the TβRIIDN retroviral vector, the difference in TGF-β1 level between malignant and benign cells, although it still existed, was reduced when compared with that of the GFP vector controls. Following blockade of TGF-β1 signaling by TβRIIDN, the endogenous TGF-β1 level deceased significantly in DU145 and PC3, while the level did not change significantly in BPH1 and RWPE1. To validate the above result, we inhibited endogenous TGF-β1 by a neutralizing monoclonal antibody to TGF-β (1D11) for 12 hour and we determined the level of TGF-β1 mRNA. As 1D11 is able to neutralize all 3 TGF-β isoforms (TGF-β1, 2, 3), Fig. 1C showed that treatment with 1D11 resulted in a significant reduction in the basal level of TGF-β1 mRNA in malignant cells but not in benign cells.
These results suggest that TGF-β1 auto-induction contributed, at least in part, to the high level of TGF-β1 expression in malignant cells, but there was no TGF-β1 auto-induction in benign cells under the basal condition. GFP vector were routinely cultured to 50% confluence and then rinsed with PBS thoroughly, cultured in serum-free medium for 24 more hours. TGF-β1 level in the culture medium was detected by using ELISA. (C) cells at 50% confluence were rinsed with PBS thoroughly and cultured in serum-free medium for 24 hours and then 100 µg/mL 13C4 or 1D11 was added. 12 h. later, total RNA was extracted and the ratio between TGF-β1 and GAPDH mRNA (mRNA ∆TGF-β1/GAPDH) was detected by qRT-PCR. Asterisks (*) denote that the P value is less than 0.05. Horizontal bars cover the groups that are being compared for statistical significance.
Impact of ERK Activation on TGF-β1 Auto-Induction (Figure 2)
Following inhibition of ERK activation with UO126 ( Figure 2B ), autoinduction of TGF-β1 in these 4 cell lines were abrogated regardless the dosage of TGF-β1 used in the experiment. Interestingly, although following a low dose of TGF-β1 stimulation, a rapid ERK activation (p-ERK) was observed in both malignant and benign cells ( Figure  3A-3D) , at a high dose of TGF-β1, a rapid inactivation of ERK Figure  3E and 3F). This differential activation of ERK between benign and malignant prostate epithelial cells coincided with the differential auto-induction of TGF-β1. Figure 2 . Western blot analysis of the effect of 0.1 ng/mL (left) or 10 ng/mL (right) TGF-β1 on expression of phosphorylated Erk (p-Erk), total Erk (T-Erk) in DU145 (A and E), PC3 (B and F), BPH1 (C and G), and RWPE1 (D and H) over a period of 30 minutes. Cells at 50% confluence were starved with serum-free medium for overnight and then recovered with medium containing 10% fetal bovine serum for 2 hours before TGF-β1 treatment. Upon detection of p-Erk, the membrane was reprobed for T-Erk.
Mechanism for ERK Activation Change Induced by TGF-β1 (Figure 3)
It is known that TGF-β1 activates ERK through a direct phosphorylation of ShcA, which sets off the well characterized ShcA-Grb2-Sos-Ras-raf-Mek-ERK signal cascade. Our results in benign cells suggested that, aside from the above positive pathway, there should also be a TGF-β1-mediated negative regulation of ERK activation. The possible candidate of this negative pathway is most likely protein phosphatase. There are mainly 2 classes of protein phosphatases: serine/threonine protein phosphatases and protein tyrosine phosphatases (PTP). When PTP was measured, the enzymatic activity did not change significantly in these 4 cell lines with TGF-β1 treatment (data not shown). However, when the serine/threonine phosphatase was measured, although there was no significant change in enzymatic activity in malignant cells, the phosphatase activity increased significantly in benign cells following TGF-β1 treatment ( Figure 4A ). This increase was in a dose-dependent manner. This finding coincided with previous study by Sebestyen et al. Because PP2A is a main serine/threonine phosphatase and it is known that PP2A activity can be induced by TGF-β1, leading to the deactivation of ERK, it is likely that PP2A may be the candidate phosphatase in the present system. Okadaic acid (OA) is an inhibitor of serine/threonine phosphatases, 10 nM of which will inhibit the PP2A but not sufficient to inhibit other phosphatases. 25 In the present study, treatment of OA (10 nM) to benign cells elicited the TGF-β1-mediated ERK activation at the high dose (10 ng/mL) of TGF-β1 ( Figure 4B ). Interestingly, following ERK activation, TGF-β1 auto-induction was observed ( Figure 4C ). This finding validated the observation that, in benign cells, TGF-β1 enhanced the PP2A activity, as reflected by the observed increase in serine/threonine phosphatase activity, resulting in ERK inactivation. (B) okadaic acid (OA) (10 nM) was added 2 hours before TGF-β1 stimulation and then TGF-β-induced P-ERK change was detected in benign cells. To measure the impact of OA itself on P-ERK, cells without OA treatment were used as control. (C) Effect of OA on the high dose of TGF-β1 auto-induction in benign cells. OA was added 2 hours before TGF-β1 treatment and then cells were cultured for another 12 hours. (D) Effect of varying dosages of TGF-β1 on immunoprecipitation with antibody against TβRI. Reaction was stopped at 15 minutes after TGF-β1 treatment. PP2A-Bα was probed by western blot analysis in PC3, DU145, BPH1, and RWPE1 cells. Asterisks (*) denote that the P value is less than 0.05. Horizontal bars cover the groups that are being compared for statistical significance.
Disscusion:
The present results indicate that a low level of TGF-β1 can auto-induce itself in both benign and malignant prostate epithelial cells. However, in benign cells, recruitment of PP2A by TβRI provides a mechanism to terminate the auto-induction at high dose of TGF-β1, while in malignant cells, because of a defective recruitment of PP2A by TβRI, TGF-β1 auto-induction is runaway, which contributes to the TGF-β1 overexpression in these cells. Here we demonstrate both ERK and PP2A play roles in TGF-β1 auto-induction in benign prostate cells, whereas in malignant prostate cells the TGF-β1 induced PP2A pathway was defective. Because the antibody used in this study detects the tyrosine phosphorylated site of ERK, ERK cannot be a direct substrate of PP2A here. Further studies are needed to investigate how PP2A exactly deactivates ERK. Part 2. We have successfully established that neutralizing TGF-beta antibody (1D11) is safe for administration into experimental mice and that TGF-beta antibody can prevent tumor metastasis, mainly throughthe prevention of Erk activation, which subsequently presented DNA hypermethylation in the target cells. The recognition of TGF-beta mediated DNA hypermethylation is indeed exciting and novel. We will devote the remainder of the funding period to investigate the mechanism of regulation of DNMT expression by Erk activation in response to TGF-beta in cancer cells. (Zhang Q, et al, PloS ONE, 2011) 2. 1. DNMTs expression is mediated through a phosphorylated-ERK dependent pathway (Figure 4) In this study, as we found in Figure 4 A. The benign BPH-1 and RPWE-1 cells express significantly higher baseline levels of p-ERK than the PC-3 cells. There is a time dependent positive correlation between treatment with TGF-β1 and the expression of p-ERK in PC-3 cells. The levels of p-ERK continue to increase during all subsequent time points up to 30 minutes after TGF-β1 addition. In contrast, the expression of p-ERK is rapidly (<5 minutes) inhibited after TGF-β1 exposure in benign cells in a fashion that is independent of the total ERK protein expression. B. Figure 5 ) To validate whether TGF-β is responsible for the activation of ERK and up-regulation of DNMTs which may be involved in tumor progression in vivo, we conducted experiments using a mouse xenograft CaP model which involved the injection of CaP tumor cells (TRAMP-C2 cells stably transfected with a HSV1-tk-GFPluciferase reporter, 5×10 6 /each mouse). Tumor growth was followed using luciferase imaging. We used three groups of mice to better understand the effects of TGF-β on ERK activation and DNMT expression: Group 1: mice (n = 10) received regular injections of the TGF-β neutralizing antibody, 1D11. Group 2: mice (n = 10) received the isotype control antibody, 13C4, at the same regular intervals as Group 1. Group 3: received no treatment after xenograft injection as a control. We found that tumor growth was significantly inhibited with anti-TGF-β 1D11 antibody, treatment (Group 1) compared with the other two groups (Fig. 5A , 5B). In fact, at the end of the 45-day treatment period, one of the ten mice (10%) in this group was free of tumor. In the remaining 9 mice, the average tumor weight and volume was 5.3 g and 6.85 cm 3 , respectively. In comparison, tumors were found in all mice in Groups 2 and 3. The average weight and volume of tumors in the 10 animals treated with the control antibody (Group 2) or no treatment (Group 3) was significantly greater (Fig. 5C ). There were no metastases in all the groups as assessed by bioluminescence imaging. Immunohistochemical analyses of the primary tumors revealed that the expression of p-ERK and DNMTs in animals in Group 1 were significantly lower than those of the other two groups (Fig. 5D ). To examine the utility of these markers as possible prognostic tools, we correlated the expression levels of the above TGF-β related biomarkers of each tumor with the clinical outcome of the corresponding patient using the database of Northwestern University's Prostate SPORE. The log rank test was used determine whether or not these various markers correlated with biochemical recurrence (PSA>0.2 ng/ml after radical prostatectomy). Variables of interest included all TMA markers, clinical stage, clinical Gleason's score, which was grouped as 4-6, 7, 8-10, surgical margin status, PSA doubling time, and patient age. As mentioned above, all specimens were assigned a value between 0-3 based upon the percentage of cancer cells showing a positive staining. A Kaplan Meier curve was generated for each of the above significant variables. The results were showed in the Figure 6 . A. Kaplan Meier curve was generated for significant variables. TGF-β1, p-Smad2, p-ERK, pathologic Gleason Score and DNMT1, TβRI were all predictors of biochemical recurrence. B. DNMT1, pathologic Gleason score was analyzed as two different groups, and there was a significant difference in the survival curves. C. Cox Proportional Hazards Model only includes DNMT1, grouped as below 3 and 3, and pathologic Gleason score sum of patients, grouped as below 8, or above. Using our dataset, patients with tissue level DNMT1 of 3 had a 3.53 times higher biochemical recurrence rate than patients with lower tissue levels of DNMT1. Patients with Gleason score sum ≥8 have a 2.27 times higher biochemical recurrence rate compared to patients with Gleason score sum <8.
In summary, our findings indicate that DNMTs expression levels are correlated with invasive capabilities in cultured human CaP cell lines. Additionally, we found that tumor-derived TGF-β and ERK are involved in the regulation of DNMTs in these cell lines. Inhibition of TGF-β in vivo results in the corresponding inhibition of DNMTs, and appears to significantly decrease tumor growth. In addition, we confirmed that the expression levels of TGF-β, ERK and DNMTs in tissue specimens obtained at the time of prostatectomy mimicked our findings in cell culture. Finally, we found that high expression levels of DNMT1 may potentially be used to predict biochemical recurrence in patients following radical prostatectomy.
REPORTABLE OUTCOMES:
As a result of this research funded by the Department of Defense, we have completed two manuscripts (see appendix).
CONCLUSIONS:
Our findings indicate that tumor cell-derived TGF-beta may induce the insensitivity to growth inhibition by this cytokine. There is a feedback loop appears to regulate the expression of TGF-beta Receptors through both ERK activation and DNMTs expression and appears to impact on the invasive potential of prostate cancer cells. In addition, this pathway appears to have clinical utility as both a therapeutic option and a prognostic tool. Inhibition of TGF-beta in vivo appears to significantly decrease tumor growth and the number of cancer cells which express either TGF-β, p-ERK, and DNMT. Finally, high levels of TGF-betainduced expression of DNMT1 may potentially be used to reliably predict biochemical recurrence in patients following radical prostatectomy.
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Barrack ER. M any cancer cells, including prostate cancer, are able to overexpress TGF-␤1. 1 Aside from the growth inhibitory effect, TGF-␤1 can also stimulate extracellular matrix production, promote angiogenesis, facilitate invasion, and suppress the host immune system. 2 Thus cancer cells may circumvent the suppressive effects of TGF-␤1, especially for aggressive cancer cells. Therefore for these cancer cells, it is possible that approaches to disrupt the TGF-␤1 overexpression may offer a strategy to suppress the aggressive phenotype. To achieve this goal, we must first understand the mechanism through which these tumor cells produce more TGF-␤1 than their benign counterparts. Yet, little is known about the regulation of TGF-␤1 overexpression. The most potent inducer of TGF-␤1 is itself. 3 It has been shown that TGF-␤1 can induce its own mRNA transcription and protein synthesis in various cells. [4] [5] [6] [7] [8] The exact mechanism of TGF-␤1 auto-induction is still not clear. Previous investigations showed that extra-cellular signal-regulated kinase (ERK) and c-jun N-terminal kinase (JNK) are involved in TGF-␤-induced AP1complex, which contributes to TGF-␤1 auto-induction. 5 Further, Smad3/Smad4 takes part in the TGF-␤1 mRNA transcription, 9 whereas p38 pathway influences de novo synthesis of TGF-␤1. 9 Among these pathways, ERK activation by TGF-␤1 has been shown to be essential for TGF-␤1 auto-induction. 10 However, the effect of TGF-␤1 on ERK activation remains controversial and seems to be dependent on cellular context. Many studies described that TGF-␤1 could activate ERK; [11] [12] [13] [14] [15] however others reported that TGF-␤1 inactivated or had no effect on ERK. [16] [17] [18] [19] [20] Therefore it is reasonable to deduce that TGF-␤1 auto-induction through ERK activation is also cellular context dependent. The aim of the present study is to elucidate whether there is a difference in TGF-␤1 auto-induction between malignant and benign prostate epithelial cells and whether TGF-␤1 auto-induction contributes to TGF-␤1 overexpression in cancer cells.
MATERIAL AND METHODS

Cell Lines, Reagents, and Retroviral Vector Transduction
Human prostate cancer cell lines, PC3, DU145, and the benign human prostate epithelial cell line, RWPE1, were obtained from American Type Culture Collection (Manassas, VA). Another human benign prostate epithelial cell line, BPH1, was kindly provided by Dr. Simon Hayward of Vanderbilt University. All cells, unless otherwise specified, were routinely maintained in culture medium RPMI-1640 with 10% fetal bovine serum (FBS) and kept in a 37°C, 5% CO 2 incubator. TGF-␤1 was obtained from R&D Systems (Minneapolis, MN). The MEK1/2 inhibitor, UO126, was obtained from Cell Signaling (Danvers, MA). The TGF-␤ neutralizing monoclonal antibody (1D11) and the isotype control IgG Ab (13C4) were kindly provided by the Genzyme Corporation (Framingham, MA).
In indicated experiments, cells were transduced with TGF-␤ receptor II-dominant negative (T␤RIIDN) retroviral vector or the GFP vector as previously described. 21, 22 Figure 1A is a schematic diagram of the murine stem cell virus (MSCV) retroviral construct containing a truncated sequence of the human T␤RIIDN, lacking the intracellular kinase signaling domain, which was cloned into the pMig-internal ribosomal entry sequence (IRES)-GFP vector. The control construct (not shown) contained the GFP vector only and without the T␤RIIDN sequences (325-902 bp). The transduction efficiency was Ͼ90%.
Enzyme-Linked Immunosorbent Assay
Culture medium was collected and centrifuged at 1000 g for 10 minutes, and viable cells were counted. The concentration of TGF-␤1 was detected by a human TGF-␤1 enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems) following the manufacturer's instructions as described previously 22 (data expressed as pg/mL/10 6 cells/24 h).
Immunoprecipitation
Pierce Crosslink Immunoprecipitation kit (Pierce, Rockford, IL) was used for protein immunoprecipitation following the manufacturer's recommendations. Briefly, cells were harvested following the specified treatment with IP Lysis/Wash buffer plus 1% protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO). Protein concentration was assayed and adjusted to 1 mg/mL with the lysis/wash buffer. An aliquot of 600 L of cell lysates was precleared by using 20 L Pierce Control Agarose Resin. TGF-␤ type I receptor (T␤RI) antibody (5 g) (Santa Cruz Biotechnology, CA) was bound to 20 g of Pierce Plus Agarose in a Pierce Spin Column. After incubation for 60 minutes in room temperature, the antibody and agarose was crosslinked by DSS supplied by the kit. Precleared lysate was immunopreciptated by the crosslinked antibody and agarose mixture for overnight on 4°C. Control agarose resin in the kit was used as a negative control when western-blot analysis was conducted.
Western Blot Analysis
Cell lysates were prepared by using cell lysis buffer (Cell Signaling, Danvers, MA) supplemented with 1 mM PMSF and 1% protease inhibitor cocktail (Sigma-Aldrich) or eluted from the protein immunoprecipitation. Western blot analysis was performed as described previously. 18 The following antibodies were used: p-ERK1/2 (Cell Signaling, Danvers, MA), ERK1/2 (Cell Signaling), PP2A B␣ antibody (Cell Signaling), Goat antimouse HRP-labeled secondary antibody (Bio-Rad Laboratories, Hercules, CA) and goat anti-rabbit HRP-labeled secondary antibody (Bio-Rad Laboratories). (B) cells infected with T␤RIIDN or GFP vector were routinely cultured to 50% confluence and then rinsed with PBS thoroughly, cultured in serum-free medium for 24 more hours. TGF-␤1 level in the culture medium was detected by using ELISA. (C) cells at 50% confluence were rinsed with PBS thoroughly and cultured in serum-free medium for 24 hours and then 100 g/mL 13C4 or 1D11 was added. 12 h. later, total RNA was extracted and the ratio between TGF-␤1 and GAPDH mRNA (mRNA ⌬TGF-␤1/GAPDH) was detected by qRT-PCR. Asterisks (*) denote that the P value is less than 0.05. Horizontal bars cover the groups that are being compared for statistical significance.
Quantitative Reverse Transcriptase-Polymerase Chain Reaction
Total RNA was extracted by using TRIzol (Invitrogen, Carlsbad, CA) and digested with RNase free DNase I (Invitrogen) following the manufacturer' recommendations. cDNA was synthesized by using Superscript first-stand synthesis system (Invitrogen). Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) was performed by using following primers specific for TGF-␤1 (forward 5=-CCTTTCCTGCTTCTCAT-GGC-3=; reverse 5=-ACTTCCAGCCGAGGTCCTTG-3=), GAPDH (forward 5=-CAC CAC CAT GGA GAA GGC TGG-3=, reverse 5=-GAA GTC AGA GGA GAC CAC CTG-3=). The iQ SYBR Green Supermix (BioRad Laboratories) on iCycler iQ system was conducted according to the manufacturer's protocol. All qRT-PCR reactions were performed in triplicate for each cDNA sample.
Phosphatase Activity Assay
Nonradioactive Serine/Threonine Phosphatase Assay System (Promega, Madison, WI) was used according to the manufacturer's instructions. Cell lysates were prepared from 10 7 cells in 0.5 mL lysis buffer (10 mM Tris, pH 7.5; 0.1% Triton X-100; 140 mM NaCl; 1 mM PMSF; protease inhibitor cocktail) and passed through Sephadex G-25 columns to remove free phosphate. The protein concentration of the supernatant was determined (Pierce). The activity of the extract (corresponding to 2 g protein) was measured in an enzyme-specific reaction buffer (250 mM imidazole pH 7.2; 1 mM EGTA, 0.1% ␤-mercaptoethanol; 0.5 mg/mL BSA) with 1 mM phosphopeptide and Molybdate Dye/Additive incubation. Results of colorimetric optical density (OD) were read at 620 nm. Calculations were performed from parallel measurements of standard free phosphate reactions. Similarly, protein-tyrosine-phosphatase activity was assayed by using the universal Tyrosine Phosphatase Assay Kit (Promega) according to the manufacturer's instructions.
Statistical Analysis
All experiments were repeated at least 3 times. Descriptive statistics (mean and standard deviation) was applied for data analysis. Analysis of variance test (multigroups) or Student's t test (2 groups) was applied for evaluating significance. A P value Ն 0.05 was considered statistically significant.
RESULTS
Endogenous TGF-␤1 and Its Auto-Induction As indicated in Figure 1B , the basal level of TGF-␤1 in DU145 and PC3 was significantly higher than that in BPH1 and RWPE1. These results verified the well-documented phenomenon that prostate cancer cells secrete more TGF-␤1 than that of benign cells. 1 When cells were rendered insensitive to TGF-␤1 by transduction with the T␤RIIDN retroviral vector, the difference in TGF-␤1 level between malignant and benign cells, although it still existed, was reduced when compared with that of the GFP vector controls. Following blockade of TGF-␤1 signaling by T␤RIIDN, the endogenous TGF-␤1 level deceased significantly in DU145 and PC3, while the level did not change significantly in BPH1 and RWPE1. To validate the above result, we inhibited endogenous TGF-␤1 by a neutralizing monoclonal antibody to TGF-␤ (1D11) for 12 hour and we determined the level of TGF-␤1 mRNA. As 1D11 is able to neutralize all 3 TGF-␤ isoforms (TGF-␤1, 2, 3), Fig. 1C showed that treatment with 1D11 resulted in a significant reduction in the basal level of TGF-␤1 mRNA in malignant cells but not in benign cells. These results suggest that TGF-␤1 auto-induction contributed, at least in part, to the high level of TGF-␤1 expression in malignant cells, but there was no TGF-␤1 auto-induction in benign cells under the basal condition.
Auto-Induction With Exogenous TGF-␤1
Reports in the literature have shown that the phenomenon of TGF-␤ auto-induction with exogenous TGF-␤1 in many cell types. 8 The results of the present study ( Figure 2A ) demonstrated that at a low dose (0.1 ng/mL) of exogenous TGF-␤1, it induced TGF-␤1 mRNA in both benign and malignant prostate cells; however, at a high dose (10 ng/mL), auto-induction occurred only in malignant cells. It was well documented that this increase in mRNA was consistent with an increase in de novo TGF-␤1 synthesis. 8, 9 Impact of ERK Activation on TGF-␤1 Auto-Induction Following inhibition of ERK activation with UO126 ( Figure 2B ), auto-induction of TGF-␤1 in these 4 cell lines were abrogated regardless the dosage of TGF-␤1 used in the experiment. This observation was consistent with the study by Zhang et al, who reported that ERK Figure 2 . TGF-␤1 mRNA transcription induced by exogenous TGF-␤1. (A) cells at 50% confluence were rinsed with PBS thoroughly and cultured in serum-free medium for 12 hours with or without exogenous TGF-␤1 and then TGF-␤1 and GAPDH mRNA level was detected. (B) cells were treated as above, but 2 hours before TGF-␤1 administration, 5 M UO126 was added into the serum-free medium. ERK activation was inhibited thoroughly by this dose of UO126 (not shown). Asterisks (*) denote that the P value is less than 0.05 compared with the control.
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activation was linked to TGF-␤1 auto-induction. 10 Interestingly, although following a low dose of TGF-␤1 stimulation, a rapid ERK activation (p-ERK) was observed in both malignant and benign cells ( Figure 3A-3D) , at a high dose of TGF-␤1, a rapid inactivation of ERK occurred in benign cells ( Figure 3G and 3H) but the rapid ERK activation continued in malignant cells (Figure 3E and 3F ). This differential activation of ERK between benign and malignant prostate epithelial cells coincided with the differential auto-induction of TGF-␤1.
Mechanism for ERK Activation Change Induced by TGF-␤1
It is known that TGF-␤1 activates ERK through a direct phosphorylation of ShcA, which sets off the well characterized ShcA-Grb2-Sos-Ras-raf-Mek-ERK signal cascade. [11] [12] [13] [14] Our results in benign cells suggested that, aside from the above positive pathway, there should also be a TGF-␤1-mediated negative regulation of ERK activation. The possible candidate of this negative pathway is most likely protein phosphatase. There are mainly 2 classes of protein phosphatases: serine/threonine protein phosphatases and protein tyrosine phosphatases (PTP). When PTP was measured, the enzymatic activity did not change significantly in these 4 cell lines with TGF-␤1 treatment (data not shown). However, when the serine/ threonine phosphatase was measured, although there was no significant change in enzymatic activity in malignant cells, the phosphatase activity increased significantly in benign cells following TGF-␤1 treatment ( Figure 4A ). This increase was in a dose-dependent manner. This finding coincided with previous study by Sebestyen et al. 20 Because PP2A is a main serine/threonine phosphatase and it is known that PP2A activity can be induced by TGF-␤1, leading to the deactivation of ERK, 23, 24 it is likely that PP2A may be the candidate phosphatase in the present system. Okadaic acid (OA) is an inhibitor of serine/threonine phosphatases, 10 nM of which will inhibit the PP2A but not sufficient to inhibit other phosphatases. 25 In the present study, treatment of OA (10 nM) to benign cells elicited the TGF-␤1-mediated ERK activation at the high dose (10 ng/mL) of TGF-␤1 (Figure 4B) . Interestingly, following ERK activation, TGF-␤1 auto-induction was observed ( Figure 4C ). This finding validated the observation that, in benign cells, TGF-␤1 enhanced the PP2A activity, as reflected by the observed increase in serine/threonine phosphatase activity, resulting in ERK inactivation. PP2A has 3 subunits: scaffold subunit A, regulatory subunit B, and catalytic subunit C. The PP2A core enzyme, consisting of A and C subunits, must interact with the regulatory subunit B to form a heterotrimeric holoenzyme to obtain the function of de-phoshorylation to the substrate. It is known that there is a physical interaction between the activated T␤RI and PP2A-B␣, a WD-40 repeat regulatory subunit of PP2A and PP2A activity increases after this interaction. 26 To investigate whether there was physical interaction between PP2A-B␣ and T␤RI in these 4 cell lines, we performed an immunoprecipitation experiment using antibody to T␤RI and probed for PP2A B␣ in the precipitates by western blot analysis. Indeed, there was an increase in PP2A-B␣ with T␤RI pull-down following TGF-␤1 treatment in a dose dependent manner in BPH1 and RWPE1 cells ( Figure 4D ). However, TGF-␤1-induced PP2A B␣ recruitment by T␤RI was not observed in DU145 or PC3 cells, suggesting a defect in recruitment of PP2A B␣ by T␤RI. The total level of PP2A B␣ protein in the total lysate of these 4 cell lines, as determined by western-blot analysis, was abundant and was not significantly different with different doses of TGF-␤1 treatment (data not shown).
COMMENT TGF-␤1 is a pleiotropic cytokine that can mediate a wide spectrum of cellular effects through a variety of signaling pathways. 27 It is a well-known feature that sometimes different pathways cooperate to orchestrate a certain cellular effect. Here we demonstrate both ERK and PP2A play roles in TGF-␤1 auto-induction in benign prostate cells, whereas in malignant prostate cells the TGF-␤1 induced PP2A pathway was defective. Because the antibody used in this study detects the tyrosine phosphorylated site of ERK, ERK cannot be a direct substrate of PP2A here. Further studies are needed to investigate how PP2A exactly deactivates ERK.
As the physical and functional interaction between T␤RI and PP2A B␣ depends on the integrity and activation of both T␤RI and T␤RII, 26 although functional and somatic mutations of T␤RI and T␤RII in prostate cancer have been demonstrated before, 1 further studies should be conducted to determine whether the defective PP2A recruitment by T␤RI in prostate malignant cells is the result of mutations in these receptors.
Although several hypotheses have been proposed to justify the high level of TGF-␤1 overexpression in malignant cells, 2,28 a plausible mechanism remains elusive. In the present study, we observed a differential TGF-␤1 signaling pathway between benign and malignant cells which leads to a differential auto-induction of TGF-␤1 through a defective PP2A recruitment by T␤RI in malignant cells. It should be pointed out that, under special conditions, such as low TGF-␤1 microenvironment, benign cells can also mediate TGF-␤1 auto-induction. Perhaps, this is a feedback mechanism in an effort to maintain homeostasis in benign cells. Once the level of TGF-␤1 reaches a certain threshold in the benign environment, a sufficient level of PP2A will be recruited by T␤RI, resulting in inactivation of ERK and termination of TGF-␤1 auto-induction. However, in cancer cells, because of the defective recruitment of PP2A by T␤RI, the auto-induction of TGF-␤1 is runaway and constitutes a vicious cycle leading to overexpression of TGF-␤1 and tumor progression. It is known that the average TGF-␤1 in human serum 29 and semen 30 is higher than 10 ng/mL. The high dose of TGF-␤1 used in the present study that induced an auto-induction of TGF-␤1 in malignant cells but not in benign cells may have physiological significance. Further studies should be conducted to determine whether this defective recruitment of PP2A by T␤RI is a widespread phenomenon among most malignant cells rather than limited to the 2 cancer cell lines used in the present study. If this phenomenon is validated in other malignant cells, it may offer a novel approach to prevent tumor invasion and tumor progression.
CONCLUSIONS
The present results indicate that a low level of TGF-␤1 can auto-induce itself in both benign and malignant prostate epithelial cells. However, in benign cells, recruitment of PP2A by T␤RI provides a mechanism to terminate the auto-induction at high dose of TGF-␤1, while in malignant cells, because of a defective recruitment of PP2A by T␤RI, TGF-␤1 auto-induction is runaway, which contributes to the TGF-␤1 overexpression in these cells. 
, Scott Lonning
Introduction TGF-b is a pleiotropic growth factor that has been implicated in multiple, and often diametrically opposed functions, including cell proliferation, cell growth arrest, differentiation, and apoptosis [1] , [2] . An obvious question raised by these diverse functions is how TGF-b mediates these seemingly contradictory roles in both cancer and benign cells. In cancer cells, TGF-b acts as a growth promoter and aids in metastasis, whereas in normal cells it appears to inhibit cell growth and induce apoptosis [3] . Characteristics of aggressive prostate cancer (CaP) include a gradual loss of sensitivity to TGF-b and over-expression of TGF-b, which appears to initiate a vicious cycle for tumor progression. Although it is well known that a reduction or loss of expression of TGF-b receptors (TbRs) enables cancer cells to escape the growth inhibitory effect of TGF-b and to gain a growth advantage, the cellular mechanism(s) underlying these events in human CaP cells remains undefined. Previously, we have demonstrated that the loss of TbRs expression by promoter methylation is associated with insensitivity to TGF-b-mediated growth inhibition [4] .
DNA methylation is carried out by DNA methyltransferases (DNMTs). There are at least three functional DNMTs that have been identified in eukaryotic systems. DNMT1 has been implicated primarily in the maintenance of methylation patterns that occurs during cellular replication, and it preferentially methylates hemimethylated DNA [5] . It has been the most extensively studied maintenance methyltransferase and is abundant in tumor cells and tissues. In comparison, DNMT2 does not appear to have significant methylation activity and DNMT3L is likely to be limited to DNA methylation during germline development [5] . Finally, DNMT3A and DNMT3B are known to be de novo methylators of CpG sites [6] , which have higher methyltransferase activity for unmethylated DNA than DNMT1 and can contribute to de novo methylation during embryogenesis [7] , [8] . Although DNMT is reported to be associated with some aggressive cancers like hepatocellular carcinomas, stomach cancers, non-small cell lung cancers, lymphoma and prostate cancers [9] , [10] , [11] , [12] , [13] , its role remains controversial and the overall regulation, coordination and activity of DNMTs is unclear with different cancers. Furthermore, the mechanism of DNMTs in cancer cells and its association with invasive malignant capabilities and clinical outcomes after treatment have not been described.
We recently reported that the epigenetic regulation of TGF-binduced expression of Foxp3 may be mediated through the inactivation of extracellular signal-regulated kinases (ERK), which may down-regulate DNMTs in benign cells [14] . As stated above, CaP cells and tissue are insensitive to TGF-b-mediated growth inhibition and have promoter methylation patterns which decrease the expression of TbRs (TbRI and TbRII) [4] , [15] , [16] . Taken together, these results indicate that the insensitivity to TGF-b in some CaP cells is at least partly due to the promoter methylation of TbRs. These findings have led us to explore the following two hypotheses in the present study: 1) There may be crosstalk between tumor derived TGF-b and DNMTs which is related to methylation in cancer; 2) DNMTs may be closely associated with the prostate cancer progression and outcomes following radical prostatectomy. To our knowledge, this subject matter has yet to be reported.
The purpose of our study was several-fold. First, we sought to investigate the corresponding changes in DNMT and TbRs expression and ERK activation after treating CaP cells with varying degrees of invasive capability and benign prostate epithelial cells with TGF-b. Next, we examined the effect of a neutralizing TGF-b antibody on the expression of DNMTs and tumor growth in vivo using a xenograft model. Finally, we determined whether activation of DNMTs was associated with biochemical recurrence following radical prostatectomy.
Materials and Methods
(A detailed explanation is presented in Method S1)
Cell Lines
The mouse CaP cell line TRAMP-C2 cells was obtained from Dr. N. Greenberg [12] . The benign human prostate epithelial cell line, RWPE-1, was purchased from American type culture collection (ATCC). BPH-1 cells were kindly provided by Dr. Simon Hayward. Four variants of the human CaP PC-3 cell lines (PC-3, PC-3M-Pro4, PC-3M and PC-3M-LN4) with varying degrees of invasive capabilities were kindly provided by Dr. Fidler and Dr. Pettaway [17] , [18] , [19] , [20] . The reason we chose PC-3 variants was because these variants originate from the same cell line, but vary in their aggressive capabilities. The results of signaling regulation were more comparable in contrast to using the different kinds of CaP cell lines. For some experiments, cells were rendered insensitive to TGF-b (as a negative control) by introducing a TbRIIDN as previously described [21] , [22] . In some experiments, cells were treated with or without TGF-b1 or MEK inhibitor U0126 (Promega). Finally, some experiments involved the use of Anti-TGF-b (1, -2, -3) neutralizing mAb (clone 1D11; a gift from Genzyme Corporation) as previously described [23] , [24] . (Method S1).
TGF-b1 ELISA
RWPE-1, BPH-1 and all PC3 variants and the corresponding TbRIIDN infected cell lines were cultured in fresh serum-free media for 24 hours. TGF-b1 ELISA was carried out using the Human TGF-b1 Immunoassay Kit (R&D Systems) (Method S1). 
Western blot analysis
Western blot analyses were performed to compare TbRs, DNMTs and ERK expression after different treatments over time (Method S1).
Methylation-Specific PCR (MSP) and Sequencing
MSP for the methylation status of TbRs was performed according to our previous report [4] . The methylated sites in cytosine positions with/without treatment of 5-Aza or TGF-b were identified.
Immunofluorescence and Co-staining
Immunofluorescence studies were performed on all PC-3 cell line derivatives as previously described [22] , [25] . For colocalization of DNMTs and phosphorylated ERK (p-ERK), cells were analyzed by using nucleus (DAPI)-DNMTs(TR)-p-ERK (FITC) triple staining (Method S1).
Quantitative RT-PCR
Human benign prostate epithelial cells RWPE-1 and BPH-1, and CaP PC-3 serials) were cultured in fresh media for 24 hours, then exposed for 24 hours to either: 1) external recombinant TGFb1 (10 ng/ml), 2) anti-TGF-b neutralizing monoclonal Ab (1D11; 5 mg/ml), or 3) MEK inhibitor U0126 (5 mM). Total RNA was extracted using an RNeasy kit (Qiagen). Primers for human for DNMTs [26] and TbRs [4] were listed in Method S1.
Cell invasion assay
Cell invasion assay (Matrigel invasion assay) was done in a 24-well Transwell chamber (8 mm pore size; CytoSelect; Cell Biolabs). Cells were plated at a density of 0.5610 6 to 1.0610 6 /mL in serum-free medium. TGF-b1 and/or Erk inhibitor UO126, 5-Aza were added directly to the cell suspension, and 24 h later, the suspension was aspirated and the invaded cells were counted with a light microscope under high magnification objective (6100; Olympus) and measured at A560 nm in a plate reader after treatment with the extraction solution.
Animal Studies
The study was initiated using the subcutaneous (sc) injection of mouse prostate cancer TRAMP-C2 cells transfected with HSV1-tk-GFP-luciferase (SFG-nTGL) reporter gene expression vector [27] , [28] into the right flank region of 30 C57BL/6 mice as described earlier [25] . Animals were randomly assigned to one of three groups following intraperitoneal injections with the specific anti-TGF-b neutralizing antibody 1D11 or control antibody 13C4 as described before [23, 24] . All the mice were sacrificed after 15 injections of antibodies and group 3 were sacrificed on the same time interval. (Method S1). This study received approval from the institutional review board of Northwestern University (Evanston, IL). Northwestern University ACUC Approval protocol number 2007-0565.'' (Letter S1).
Construction of Tissue Microarrays (TMAs) and Clinical Outcome Assement
The existing clinical case information and banked tissue established within our prostate SPORE program database at Northwestern University was used. All enrolled subjects provided written informed consent by Northwestern Memorial Hospital and the study was approved by the Northwestern University Institutional Review Board (The IRB number is 1480-002, Letter S2). A total of 243 radical prostatectomy specimens were available with associated clinical information. A series of prostate TMAs were constructed with formalin-fixed, paraffin-embedded radical prostatectomy specimens as described previously [4] , (Method S1 and Method S2).
Immunohistochemistry
All antibodies raised against DNMTs, phosphorylated ERK (p-ERK), total ERK (t-ERK), phosphorylated Smad2, TbRI and TbRII were first tested and optimized on whole-tissue sections and test arrays as previously described [4] , [17] , [29] , [30] , (Method S1 and Method S2).
Statistical Analysis. The SPSS 10.0.7 software package (SPSS, Inc.) was used for all analyses. Kaplan-Meier survival curve was analyzed by the log-rank test using the Graphpad Prism 4.02 software (Graphpad Software) (Method S1).
Results
DNMTs expression is associated with down regulation of TbRs and more invasive prostate cancer phenotypes
An ELISA assay was initially performed to determine whether there were differences in the endogenous expression levels of TGFb in different CaP cell lines when compared to benign prostate cell lines. We found that all PC-3 cell lines expressed significantly higher levels of TGF-b (62 to 6 times) compared to the BPH-1 and RWPE-1 (p,0.05). Furthermore, we found that more invasive cells (PC-3M and PC-3M-LN4) secreted almost 2 times higher baseline levels of TGF-b1 when compared with the less invasive cell lines (PC-3 and PC-3M-Pro4) (Fig. 1A) .
We confirmed that different prostate cell lines behave differently in response to exogenous TGF-b1 exposure. For example, we found that RWPE-1 and BPH-1 cells were most sensitive to exogenous TGF-b1 as their growth was inhibited by 64.1% and 61.9%, respectively, after 24 hours of treatment with TGF-b1. In comparison, PC-3 and PC-3M-Pro4 cells were only inhibited by 13.7% and 12.3%, respectively. Finally, the growth rate of PC-3M-LN4 and PC-3M was unaffected by TGF-b1 exposure (Fig. 1B) . Interestingly, in CaP cell lines, inhibition of TGF-b signaling, using the dominant negative type II TGF-b receptor (TßRIIDN) construct, was associated with significantly higher endogenous TbRII expression (using antibodies directed against the intracellular domain, because TbRIIDN includes only extracellular and transmembrane domains, but not intracellular domain) (Fig. 1C ) and higher TGF-b secretion (Fig. 1D ). In comparison, there was no difference in the expression of TGF-b in BPH-1 or RWPE-1 when they were infected with the retroviral TbRIIDN construct (Table S1 ).
In contrast to the expression of TGF-b, both TbRI and TbRII expression was significantly reduced in the more invasive cell lines, PC-3M-LN04 and PC-3M, compared with PC-3 and PC-3M-Pro4 cells (Fig. 2A) . Blockade of TGF-b signaling with the TbRIIDN vector caused an approximately two to ten-fold increase in the expression of both TbRI and TbRII in all CaP cell lines (Fig. 2B) . Taken together this suggests that increased baseline levels of TGF-b are associated with the inhibition of TbRs expression. Blockade of intracellular TGF-b signaling resulted in up-regulation of secretion of TGF-b in cancer cells.
Since promoter methylation of TbRs is associated with decreased expression [4] , we compared the expression levels of DNMTs in the different CaP cell lines. In general, the more invasive PC-3M-LN4 and PC-3M cells showed an increased expression of DNMTs, when compared to the less invasive PC-3 and PC-3M-Pro4 (Fig. 2C) . Blockade of TGF-b signaling with the TbRIIDN vector caused a $3-fold decrease in the expression of DNMTs in all CaP cell lines (Fig. 2D) , and there was a corresponding increase in the expression of both TbRI and TbRII (Fig. 2B) . The corresponding value (relative ratio of TbRs/ GAPDH, or DNMTs/GAPDH) is shown in right panels. This finding was also supported by additional confirmatory studies. Immunoblot analyses demonstrated that after treatment with 5-Aza-29-deoxycytidine (5-Aza), the expression of TbRI and TbRII in PC-3 increased dramatically. In contrast, the expression of both TbRI and TbRII decreased significantly with the treatment of TGF-b and this change could be recovered when 5-Aza is added ( Figure S1A) . Similarly, real-time PCR confirmed that the expression of both TbRI and TbRII was increased 2 to 2.5 folds after treatment of 5-Aza in PC-3 cells. Treatment with TGF-b suppressed the expressions of TbRI and TbRII 46% and 29% respectively ( Figure S1B ). We also identified the methylation status of TbRI and TbRII promoters, by using the same MSP approach and sequencing methodologies [4] . Using this technique, we found the same methylated sites as our previous study [4] in that cytosine positions 2251, 2231, 2244, 2348, 2356 and 2365 in the promoter of TbRI, and +27, +32 and 2140 for the promoter of TbRII were methylated ( Figure S1C ). PC-3 cells also have a portion of TbRI and TbRII promoters that are unmethylated. There was no significant difference observed between treatment with both 5-Aza and TGF-b or with 5-Aza alone (P.0.05) ( Figure  S1D ).
DNMTs expression is mediated through a phosphorylated-ERK dependent pathway
Our previous studies demonstrate that ERK may influence DNMT expression in benign cells [14] . We therefore sought to determine whether the level of activated ERK (phosphorylated ERK; p-ERK) is related to TGF-b-induced expression of DNMTs. To test this hypothesis, we first determined the level of p-ERK in benign prostate cells and compared it to the levels in different CaP cell lines. BPH-1 and RPWE-1 cells expressed significantly higher baseline levels of p-ERK than PC-3 cells (Fig. 3A) . Interestingly, the time course of p-ERK expression after exposure to TGF-b was different between the benign and malignant cell lines. Specifically, there was a time dependent positive correlation between treatment with TGF-b1 and the expression of p-ERK in all PC-3 cell lines. In fact, this rapid increase in p-ERK expression (4-fold) began within 5 minutes following TGF-b1 treatment. The levels of p-ERK continued to increase during all subsequent time points up to 30 minutes after TGF-b1 addition. In contrast, the expression of p-ERK was rapidly inhibited (,5 minutes) after TGF-b1 addition to the media of benign cells, in a fashion that was independent of the total ERK protein expression (Fig. 3A) . Immunofluorescence studies were subsequently used to help determine whether p-ERK and DNMTs were co-localized to the same cellular regions. To this end, confocal microscopic analyses of formaldehyde fixed immunostained PC-3 cells, in the absence or presence of TGF-b1, demonstrated co-loczalization between p-ERK and DNMTs signals. Only the cells with p-ERK immunofluorescence exhibited DNMT expression. In contrast, when PC-3 cells were rendered insensitive to TGF-b1 by transfection with the TbRIIDN, levels of both p-ERK and DNMTs were reduced dramatically as determined by immunofluorsence staining (Fig. 3B) . To better quantify this relationship between TGF-b1, p-ERK and DNMTs, we next used real time PCR. These results demonstrated that exposure to TGF-b1 for 24 hours significantly increased the expression of all three DNMTs (,16.7%-14%) in all PC-3 cell lines studied. Treatment with an antibody specific for TGF-b1 (1D11; 5 mg/ml) or the specific ERK inhibitor, UO126, led to significant down-regulation of DNMTs mRNA expression (,33.9%-52.3%, and ,41.5%-57.6% respectively, Fig. 3C ). These results suggest that TGF-b mediated expression of DNMTs is associated with an increase in p-ERK in cancer cells. Specifically, tumor derived TGF-b appears to be responsible for this ERK activation, as blockade of the original secreted TGF-b resulted in a great change in the expression of DNMTs (Fig. 3C) . These results also suggest that tumor derived TGF-b mediated ERK activation is at least one of the major mediators for TGF-b induced expression of DNMTs which lead to TbRs downregulation by promoter methylation in CaP [4] , [14] . After treatment with TGF-b, there was a significant increase in the invasive capabilities of CaP cells. Invasion of CaP cells was inhibited by either TGF-b inhibitor 1D11, or p-Erk inhibitor U0126 or DNMT inhibor 5-Aza. The inhibition of invasion by the U0126 could not be reversed by TGF-b1 treatment. Importantly, DNMTs inhibitor 5-Aza can dramatically inhibited the CaP cells invasion, even more than blockade of TGF-b or p-ERK (Fig. 3D) . This observation suggested that p-ERK was downstream factor of TGF-b, and synergistically mediates TGF-b regulated DNMTs which was closely associated with the invasive capability of CaP cells.
In vivo validation of the effects of TGF-b on ERK activation, DNMT expression, and prostate cancer growth
To validate whether TGF-b is responsible for the activation of ERK and up-regulation of DNMTs which may be involved in tumor progression in vivo, we conducted experiments using a mouse xenograft CaP model which involved the injection of CaP tumor cells (TRAMP-C2 cells stably transfected with a HSV1-tk-GFP-luciferase reporter, 5610 6 /each mouse). Tumor growth was followed using luciferase imaging. We used three groups of mice to better understand the effects of TGF-b on ERK activation and DNMT expression: Group 1: mice (n = 10) received regular injections of the TGF-b neutralizing antibody, 1D11. Group 2: mice (n = 10) received the isotype control antibody, 13C4, at the same regular intervals as Group 1. Group 3: received no treatment after xenograft injection as a control. We found that tumor growth was significantly inhibited with anti-TGF-b 1D11 antibody, treatment (Group 1) compared with the other two groups (Fig. 4A, 4B ). In fact, at the end of the 45-day treatment period, one of the ten mice (10%) in this group was free of tumor. In the remaining 9 mice, the average tumor weight and volume was 5.3 g and 6.85 cm 3 , respectively. In comparison, tumors were found in all mice in Groups 2 and 3. The average weight and volume of tumors in the 10 animals treated with the control antibody (Group 2) or no treatment (Group 3) was significantly greater (Fig. 4C ). There were no metastases in all the groups as assessed by bioluminescence imaging. Immunohistochemical analyses of the primary tumors revealed that the expression of p-ERK and DNMTs in animals in Group 1 were significantly lower than those of the other two groups (Fig. 4D ).
DNMTs correlates with clinical characteristics
To evaluate the association between TGF-b and the induction of DNMTs in CaP specimens, we compared the expression levels of TGF-b1, ERK, p-ERK, TbRI, TbRII, p-Smad2, and DNMTs in archived tissue microarray specimens obtained at the time of radical prostatectomy and correlated them with corresponding patients' clinical and pathologic characteristics (Table S2 . Each marker was assigned a value of 0 (,20% cell immunostaining), 1 Figure  S2 ''. We found that a high level of expression of TGF-b1, p-ERK and DNMTs coupled with a low level of expression of TbRI, TbRII, and p-Smad2 was associated with adverse pathologic features, such as higher Gleason's grade (Fig. 5A, Fig. 5B , Table  S3 ). These results correspond to our finding in PC-3M-LN4 and PC-3M cells that TGF-b induced DNMTs are associated with clinically more aggressive phenotypes. We found a significant correlation between the expression of TGF-b1 and DNMTs in these tissue microarray specimens. There was also a significant correlation between TGF-b and p-ERK, TGF-b and TbRI, p-ERK and DNMT1, p-ERK and DNMT3A, p-ERK and DNMT3B respectively. In addition, we found a significant correlation between the expression levels of all three of the DNMTs. There were inverse relationships between DNMTs and TbRs, DNMT1.vs. TbRI, DNMT1.vs. TbRII, DNMT3A vs. TbRII (Table S3 ).
DNMTs is associated with biochemical recurrence in prostate cancer patients after radical prostatectomy
To examine the utility of these markers as possible prognostic tools, we correlated the expression levels of the above TGF-b related biomarkers of each tumor with the clinical outcome of the corresponding patient using the database of Northwestern University's Prostate SPORE. The log rank test was used determine whether or not these various markers correlated with biochemical recurrence (PSA.0.2 ng/ml after radical prostatectomy). Variables of interest included all TMA markers, clinical stage, clinical Gleason's score, which was grouped as 4-6, 7, 8-10, surgical margin status, PSA doubling time, and patient age. As mentioned above, all specimens were assigned a value between 0-3 based upon the percentage of cancer cells showing a positive staining. A Kaplan Meier curve was generated for each of the above significant variables.
Expression levels of TGF-b1, p-Smad2, p-ERK, pathologic Gleason Score and DNMT1, TbRI were associated with biochemical recurrence after radical prostatectomy (Fig. 6A . B, Table S4 ). The degree of DNMT1 expression correlated significantly with biochemical recurrence [P = 0.0043 using 4 expression groups; (0, 1, 2, 3; P = 4610 204 using 2 groups; low expression (0, 1, 2) vs high expression (3)]. DNMT3A and DNMT3B, surgical margin status, TGF-b type II receptor expression level and PSA doubling time were not associated with biochemical recurrence (p.0.05). To determine the best model for predicting PSA recurrence, a Cox Proportional Hazards Model was fit to include all the significant variables and backward selection method was used to eliminate non-significant variables. The final selected model includes DNMT1, grouped as below 3 (low expression) or above 3 (high expression; log Rank P = 0.002; hazard ratio = 3. 53; 95% CI 1.6-7.78), and pathologic Gleason score sum of patients, grouped as below 8, or above (log Rank P = 0.034; hazard ratio = 2.27; 95% CI 1. 06-4.83) (Fig. 6C , Table  S5 ). Patients whose tumors had a DNMT1 expression level of 3 (high expression) had a 3.53 higher risk of recurrence than patients with lower scores of DNMT1 in the tumor. Even in patients with low Gleason grade (#6), there was a high risk of recurrence if high levels of DNMT1 expression were present. A high DNMT1 expression was independently associated with biochemical recurrence, irrespective of Gleason score. There was no correlation between PSA doubling time and the expression levels of DNMT1.
Discussion
Many malignancies, including CaP, exhibit aberrant methylation within the promoter regions of genes associated with a loss of function [31] , [32] , [33] . Presumably, this loss of function contributes to the development and progression of the disease. DNMTs are the major mediators responsible for the hypermethylation of the promoter regions of many genes encoding for signaling factors including the TbRs promoter [4] , which may subsequently inhibits TbRs translation which ultimately results in the insensitivity to the normal inhibitory effects of TGF-b, uninhibited growth and progression of cancer [4] , [34] , [35] , [36] . Although DNMTs are recognized as important regulators of transcription of carcinogenesis [37] , [38] , [39] , [40] , [41] , [42] , and have been a topic of considerable interest in the last few years, their assessment in vivo and within human specimens remains uncertain. Our study findings demonstrate that high level of expression of DNMTs is associated with more aggressive phenotypes of CaP, lower expression of TbRs, and lower sensitivity to the inhibitory role of TGF-b.
The molecular mechanisms which govern regulation of DNMTs have been largely unknown [43] , and the relationship(s) between DNMTs and TGF-b in CaP have yet to be explored. Although other factors like c-Jun may be involved in the process [44] , ERK appears to be an obligatory switch for TGF-bmediated expression of DNMTs in CaP, although the effect of TGF-b on ERK activation remains controversial [45] , [46] . More recently we reported that there was a differential activation of ERK between benign and malignant cells in response to TGF-b [14] , [47] . In our prior studies involving benign cells, we reported that TGF-b exposure, ERK inactivation and DNMTs down regulation contribute to the expression of Foxp3 in benign immune cells [14] . In the present study, higher expression levels of DNMTs were found to be associated with CaP with higher invasive capabilities when compared with CaP cells with lower invasive capabilities. Interestingly, we found that increased levels of DNMTs were associated with increased levels of TGF-b and p-ERK, and decreased levels of TbRs. In contrast, our hypotheses were verified by a serial of blockade assays, blockade of TGF-b signaling using the TbRIIDN or neutralizing antibody 1D11, decreased the levels of DNMTs between 50%-90% in more invasive cell lines, and to a lesser degree (30-50%) in the less invasive cell lines. These findings indicate that tumor-derived TGF-b is a major mediator involved in the regulation of DNMTs and TbRs in human CaP cells, and this process correlates with more invasive phenotypes. Meanwhile, down regulation of DNMT expression by blockade of TGF-b is associated with an up-regulation of naïve TbRs expression. These findings, taken together with results from our previous study, suggest that tumor- ..
:.300 Based upon the above findings, we postulate that tumor-derived TGF-b can regulate its receptors by a potential feedback loop which is mediated by activation of ERK. Some other signaling factors like Serine/threonine protein phosphatases 2 (PP2A) [48] may be involved in this procedure. P-ERK may subsequently activate the transcription factors in the DNMTs promoter and increases the expression of DNMTs which methylates TGF-b receptor promoter regions resulting in the loss of growth inhibition mechanisms that are normally induced by TGF-b. Simultaneously, the downregulation of TbR expression and low level of TGF-b signaling may act as a positive feedback mechanism to induce the reflexive stimulation of TGF-b secretion in CaP. These potential feedback loops could explain the reduced expression of TbRs and large amounts of TGF-b that have been observed in advanced CaP. Our in vivo xenograft model also demonstrated that inhibition of DNMTs correlated to a lower tumor weight and cancer proliferation rate. These results suggest that the expression of DNMTs is associated with aggressive malignant phenotypes, tumor growth, and progression in vivo. In combination with our Figure 4 . TGF-b induced DNMTs is associated with growth of prostate cancer in vivo. A. IVIS 100 imaging system was used to monitor tumor growth in real-time. We found that tumor growth is inhibited dramatically with the treatment of 1D11 compared with Group 2 (13C4 treatment) and 3 (No treatment control). B. 1D11 treatment inhibits the tumor growth in a time dependent manner. C, At the end of the 45-day treatment period, mice were sacrificed and tumors were isolated. The average tumor weight and volume was 5.3 g and 6.85 cm 3 , respectively in 1D11 treatment group. In comparison, the average weight and volume of tumors in the 10 animals treated with the control 13C4 was significantly greater at 15. [4] , we found that DNMTs is an important factor and predictor related to CaP progression.
Furthermore, the close correlation between TGF-b, ERK and DNMTs in tissue microarray specimens indicates that this cascade of signal events is likely not only associated with aggressive malignant phenotypes in vitro, but may also be involved with progression of CaP in humans. Based on our results, during progression of prostate cancer, an attenuation of expression of TGF-b receptors facilitates tumor cells escaping from the growth inhibition by TGF-b which is Smad dependent. Meanwhile, the Smad-independent pathway, such as p-ERK and DNMT signaling could be induced by TGF-b and results in the more aggressive phenotypes.
Our data shows that increased expression of DNMTs is highly correlated with both the expression levels of TGF-b1 and p-ERK. Furthermore, there was a significant correlation between the levels of DNMTs and Gleason grade, which further supports our findings that DNMTs are associated with more invasive CaP phenotypes. This finding is similar to recent reports suggesting that DNMT1 is associated with lung cancer progression [49] . The present results demonstrate that DNMT1 is associated with biochemical recurrence in CaP patients seven years following radical prostatectomy. Thus, patients with higher tissue expression levels of DNMT1 are at increased risk for biochemical recurrence compared to those with lower tissue expression levels. The relationship between DNMT1 Figure 6 . TGF-b-induced DNMT1 predicts prostate cancer recurrence. A. Kaplan Meier curve was generated for significant variables. TGF-b1, p-Smad2, p-ERK, pathologic Gleason Score and DNMT1, TbRI were all predictors of biochemical recurrence. B. DNMT1, pathologic Gleason score was analyzed as two different groups, and there was a significant difference in the survival curves. C. Cox Proportional Hazards Model only includes DNMT1, grouped as below 3 and 3, and pathologic Gleason score sum of patients, grouped as below 8, or above. Using our dataset, patients with tissue level DNMT1 of 3 had a 3.53 times higher biochemical recurrence rate than patients with lower tissue levels of DNMT1. Patients with Gleason score sum $8 have a 2.27 times higher biochemical recurrence rate compared to patients with Gleason score sum ,8. doi:10.1371/journal.pone.0025168.g006 TGF-b-Induced DNMT Promotes CaP Progression PLoS ONE | www.plosone.orgexpression and biochemical recurrence is independent of Gleason grade. Although other variables including TGF-b1, p-ERK, Gleason grade were also showed significantly associated with biochemical recurrence, the final Cox Proportional Hazards Model demonstrated that DNMT1, in combination with pathologic Gleason sum, are stronger predictors for disease outcome. The exact mechanism of this observation remains unclear, but variables involved in the signal pathway including tumor expression of DNMT1, TGF-b1, and p-ERK may be useful in predicting clinical outcome following radical prostatectomy. High expression level of DNMT1 was risk factors for biochemical recurrence in men with CaP, regardless of Gleason's score.
In summary, our findings indicate that DNMTs expression levels are correlated with invasive capabilities in cultured human CaP cell lines. Additionally, we found that tumor-derived TGF-b and ERK are involved in the regulation of DNMTs in these cell lines. Inhibition of TGF-b in vivo results in the corresponding inhibition of DNMTs, and appears to significantly decrease tumor growth. In addition, we confirmed that the expression levels of TGF-b, ERK and DNMTs in tissue specimens obtained at the time of prostatectomy mimicked our findings in cell culture. Finally, we found that high expression levels of DNMT1 may potentially be used to predict biochemical recurrence in patients following radical prostatectomy. Figure S1 Immunoblot analyses demonstrated that after treatment with 5-Aza-29-deoxycytidine (5-Aza), the expression of TbRI and TbRII in PC-3 increased dramatically. In contrast, the expression of both TbRI and TbRII decreased significantly with the treatment of TGF-b and this change could be recovered when 5-Aza is added ( Figure S1A) . Similarly, real-time PCR confirmed that the expression of both TbRI and TbRII was increased 2-2.5 folds after treatment of 5-Aza in PC-3 cells. Treatment of TGF-b suppressed the expressions of TbRI and TbRII 46% and 29% respectively ( Figure S1B ). We also identified the methylation status of TbRI and TbRII promoters, by using the same MSP approach and sequencing methodologies (4) . Using this technique, we found the same methylated sites as our previous study (4) in that cytosine positions 2251, 2231, 2244, 2348, 2356 and 2365 in the promoter of TbRI, and +27, +32 and 2140 for the promoter of TbRII were methylated ( Figure S1C ). PC-3 cells also have a portion of TbRI and TbRII promoters that are unmethylated. Interestingly, treatment with TGF-b increased the methylation status, but treatment with 5-Aza converted all methylated sites to unmethylated. The thymidine incorporation assay indicated that the proliferation of PC-3 cells were only modestly inhibited modestly by exogenous TGF-b. In comparison, 5-Aza treatment resulted in a significant inhibition of cell proliferation, regardless of whether exogenous TGF-b was added into the culture or not. There was no significant difference observed between treatment with both 5-Aza and TGF-b or with 5-Aza alone (P.0.05) ( Figure S1D 
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